jag009
★★★

NJ,
2021-07-06 21:19
(964 d 22:43 ago)

Posting: # 22462
Views: 1,195
 

 Bracketing approach for multiple strenght product EMA [Regulatives / Guidelines]

Hi all,

For drug product which have multiple strengths (lets say 3), my thinking is to run a BE study comparing highest and lowest strength, and present dissolution similarities between the three strengths + a formulation composition table showing that the formulations are proportional.

Question: What if the product release > 85% within 15 mins? If so then one can't use dissolution to demonstrate similarity.

The product is BCS class 2.

Thx

J
dshah
★★  

India/United Kingdom,
2021-07-17 13:44
(954 d 06:18 ago)

@ jag009
Posting: # 22474
Views: 906
 

 Bracketing approach for multiple strenght product EMA

Dear J!
If the dissolution is more than 85% in 15 min, then F2 would not be applicable. However, for multimedia dissolution for a BCS class II drug, there is a high possibility that in at least one media, the dissolution would be slower and thus F2 can be applied.
Regards,
Dshah
UA Flag
Activity
 Admin contact
22,912 posts in 4,806 threads, 1,635 registered users;
37 visitors (1 registered, 36 guests [including 8 identified bots]).
Forum time: 19:02 CET (Europe/Vienna)

[…] an inappropriate study design is incapable of answering
a research question, no matter how careful the subsequent
methodology, conduct, analysis, and interpretation:
Flawless execution of a flawed design achieves nothing worthwhile.    J. Rick Turner

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5